InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,268.56
(
0.14%
)
US TECH 100
22,227.20
(
0.27%
)
Dow Jones
44,459.65
(
0.20%
)
Brent Oil
68.39
(
-0.31%
)
Bitcoin
117,166.54
(
-2.28%
)
Post# of 775952
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

Lykiri

Send PM Follow Ignore
Followers 128
Posts 2111
Boards Moderated 0
Alias Born 11/22/2017

Lykiri

Re: None

Tuesday, 04/29/2025 8:38:22 AM

Tuesday, April 29, 2025 8:38:22 AM

Post# of 775952
Question

To ask the Secretary of State for Health and Social Care, when he expects the Medicines and Healthcare products Regulatory Agency will make public their decision on licensing the personalised immunotherapy developed to treat the malignant brain tumour glioblastoma, DCVax-L.


Answered on
29 April 2025

Northwest Biotherapeutics has submitted a Marketing Authorization Application to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for DCVax-L, an immunotherapy for glioblastoma. The MHRA is working with the applicant to reach a decision on this application, to ensure a thorough review that ensures quality, safety, and efficacy.

https://questions-statements.parliament.uk/written-questions/detail/2025-04-17/45872
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News
InvestorsHub NewsWire

Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM

VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM

Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM

Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM

Start posting your company's news
Only $200 per official company press release!